Lexicon Pharmaceuticals (LXRX) Accounts Payables (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Accounts Payables for 17 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables fell 71.97% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.0 million (down 71.97% YoY), while the FY2025 annual figure was $3.1 million, down 79.17% from the prior year.
• Accounts Payables eased to $3.0 million in Q1 2026 per LXRX's latest filing, from $3.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $14.8 million in Q4 2024 and bottomed at $3.0 million in Q1 2026.
• Historically, Accounts Payables has averaged $9.4 million across 5 years, with a median of $10.3 million in 2023.
• Annual changes were most pronounced in 2022 — Accounts Payables jumped 89.22% — and 2025, when it plunged 79.17%.
• Lexicon Pharmaceuticals' Accounts Payables stood at $10.4 million in 2022, then jumped by 38.42% to $14.4 million in 2023, then rose by 2.86% to $14.8 million in 2024, then slumped by 79.17% to $3.1 million in 2025, then decreased by 2.82% to $3.0 million in 2026.
• Business Quant data shows LXRX's Accounts Payables at $3.0 million in Q1 2026, $3.1 million in Q4 2025, and $3.8 million in Q3 2025.